News
ABUS
2.730
-1.80%
-0.050
Arbutus Biopharma Announces Q1 2024 Financial Update
TipRanks · 1d ago
ARBUTUS TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE
Reuters · 1d ago
Weekly Report: what happened at ABUS last week (0408-0412)?
Weekly Report · 4d ago
Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
Arbutus Biopharma and Roivant won a crucial claims construction ruling in their patent infringement lawsuit against Moderna. The ruling opens the way for a potential win against the pharma giant, but uncertainties remain regarding the lawsuit and Arbutus' pipeline. The potential litigation payout could be significant, but the company's expensive pipeline development and cash burn rate are concerns.
Seeking Alpha · 04/10 08:22
Weekly Report: what happened at ABUS last week (0401-0405)?
Weekly Report · 04/08 09:16
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
A Delaware District Court sided with Arbutus Biopharma Corporation and Genevant Sciences in their ongoing patent infringement case against Moderna Inc. JMP Securities reiterates the Market Outperform rating with a price target of $4 on ArbutUS. The companies are suing Moderna for infringing on their patent on the COVID-19 vaccine.
Benzinga · 04/04 18:32
Arbutus Biopharma Wins Favorable Ruling Against Moderna
TipRanks · 04/04 14:07
Arbutus Biopharma Reports Claim Construction Ruling In Patent Infringement Lawsuit Against Moderna
NASDAQ · 04/04 13:45
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
Moderna Inc (NASDAQ:MRNA) stock closed lower by 2.32% on Wednesday. Arbutus Biopharma has received permission to pursue its patent infringement complaint against Moderna. The claim involves the messenger-RNA technology used in Moderna’s Covid vaccine. Moderna stock has declined by 36.54% over the past year. The company may be heading towards a Golden Cross, a bullish technical indicator.
Benzinga · 04/04 13:34
Arbutus Biopharma Price Target Maintained With a $4.00/Share by JMP Securities
Dow Jones · 04/04 12:59
JMP Securities Reiterates Market Outperform on Arbutus Biopharma, Maintains $4 Price Target
Benzinga · 04/04 12:49
ARBUTUS BIOPHARMA ANNOUNCES CLAIM CONSTRUCTION RULING IN ITS ONGOING PATENT INFRINGEMENT LAWSUIT AGAINST MODERNA
Reuters · 04/04 12:32
Investors in Arbutus Biopharma (NASDAQ:ABUS) from five years ago are still down 25%, even after 12% gain this past week
Arbutus Biopharma Corporation (NASDAQ:ABUS) share price has gained 17% in the last three months. But over the last five years the stock has lost 25% of its value. The company has added US$57m to its market cap in just the last 7 days. In the last half decade, Arbutus biopharma saw its revenue increase by 38% per year. But the company didn't make a profit in the same period.
Simply Wall St · 04/04 10:09
Arbutus Stock Soars 20% After Court Rules Against Moderna In Covid Vaccine Patent Claim
Shares in Arbutus Biopharma soared more than 20% on Wednesday, April 3. The company received permission to pursue a claim against Moderna Inc in court. Moderna developed a vaccine technology used in the Covid vaccine developed by ArbutUS. ArbutUs first filed its patent infringement complaint against Modern a in February 2022.
Benzinga · 04/03 19:37
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)
TipRanks · 04/03 19:20
UPDATE 1-Moderna shares fall after judge sides with Arbutus in patent fight
Moderna shares fall after judge sides with Arbutus in patent fight. Shares of Moderna MRNA.O fell 4% in afternoon trading. A U.S. Judge interpreted parts of the patents in ways that strengthened Ar butus' case. The lawsuit is related to Moderna's blockbuster COVID-19 vaccines.
Reuters · 04/03 18:48
BUZZ-Moderna slides after judge sides with Arbutus in patent fight
U.S. Judge sides with Arbutus in patent infringement lawsuit related to MRNA's blockbuster vaccines. Shares of Moderna slide 3.5% to $100 after the news. MRNA is a joint venture of MRNA and Roivant Sciences. Ar butus shares up 12.1% in after-hours trading.
Reuters · 04/03 18:15
Arbutus Biopharma Up Over 14%, on Pace for Largest Percent Increase Since December 2021 -- Data Talk
Arbutus Biopharma Corporation (ABUS) is currently at $2.88, up $0.36 or 14.29% from yesterday's close. Up 15.2% year-to-date. Down 90.69% from its all-time closing high of $30.94.
Dow Jones · 04/03 17:44
Arbutus Biopharma jumps after patent victory in fight with Moderna
Seeking Alpha · 04/03 16:27
Watching Arbutus Biopharma; Traders Circulate Arbutus/Genevant Vs Moderna Patent Infringement Lawsuit Claim Construction Order Court Documents
Benzinga · 04/03 16:22
More
Webull provides a variety of real-time ABUS stock news. You can receive the latest news about Arbutus Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.